VerifyNow IIb/IIIa Test, 10-Test Kit, Catalog No. 85310, 10 tests/box; 690 total tests. The VerifyNow IIb/IlIa Test is a semi-quantitative, whole blood platelet function test used to measure glycoprotein (GP) lIb/IlIa receptor blockade in patients treated with abciximab or eptifibatide. VerifyNow lIb/IlIa Test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician. The VerifyNow System is a turbidimetric based optical detection system which measures platelet-induced aggregation. The system consists of an instrument, a disposable test device and quality control materials. The VerifyNow lIb/IlIa Test is a semi-quantitative, whole blood platelet function test used to measure glycoprotein (GP) lIb/IlIa receptor blockade in patients treated with abciximab or eptifibatide.
Published December 18, 2013 · Recall initiated: November 14, 2013
Summary
FDA records medical device Class II recall Z-0482-2014, published December 18, 2013 and initiated November 14, 2013. Recalling firm: Accumetrics Inc; Status: Terminated; Reported quantity: 69 units; Lot: Lot No. WC0181H, WC0181J, WC0181K. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Accumetrics is recalling the VerifyNow IIb/IIIa 10-Test because it contains incorrect information for the amount of time in which to perform the test following collection of the patient sample. The correct instruction is to perform the test within 15 minutes of collecting the patient sample.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Accumetrics Inc
- Distributor
- Nationwide Distribution including NY, PA, DC, CT, IN, NJ, AR, TX, AZ,and NM.
- Lot
- Lot No. WC0181H, WC0181J, WC0181K
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAVerifyNow IIb/IIIa Test, Catalog No. 85310, 10-Test Kit and Catalog No. 85011, 25-Test kit. Product Usage: TheMarch 19, 2014
- FDAOpal Orthodontics by Ultradent. Avex CX2 Ceramic Orthodontic Brackets Avex CX2 ceramic brackets are intendedDecember 18, 2013
- FDAStryker Orthopaedics Cancellous Bone Screw Howmedica Osteonics Corp. Stryker France Both the 6.4 mm diameter,December 18, 2013
- FDANexGen® Complete Knee Solutions Stemmed Tibial Component Precoat NexGen Tibial Baseplates are part of theDecember 18, 2013
- FDAVerifyNow P2Y12 Assay, Part Number: 85064, All reagent lots. Product Usage: The VerifyNow P2Y12 assay deviceJune 27, 2012
- FDAVerifyNow System, part #85005-6H Product Usage: The VerifyNow P2Y12 assay device is a whole blood assay usedJune 27, 2012
Questions about this recall
Was VerifyNow IIb/IIIa Test, 10-Test Kit, Catalog No. 85310, 10 tests/box; 690 total tests. The VerifyNow IIb/IlIa Test is a semi-quantitative, whole blood platelet function test used to measure glycoprotein (GP) lIb/IlIa receptor blockade in patients treated with abciximab or eptifibatide. VerifyNow lIb/IlIa Test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician. The VerifyNow System is a turbidimetric based optical detection system which measures platelet-induced aggregation. The system consists of an instrument, a disposable test device and quality control materials. The VerifyNow lIb/IlIa Test is a semi-quantitative, whole blood platelet function test used to measure glycoprotein (GP) lIb/IlIa receptor blockade in patients treated with abciximab or eptifibatide. recalled?
Yes. FDA published recall Z-0482-2014 on December 18, 2013. Reported hazard: Accumetrics is recalling the VerifyNow IIb/IIIa 10-Test because it contains incorrect information for the amount of time in which to perform the test following collection of the patient sample. The correct instruction is to perform the test within 15 minutes of collecting the patient sample.
What should I do if I have this product?
Voluntary: Firm initiated · Letter